These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 20652780)

  • 1. Application of quantitative pharmacology in development of therapeutic monoclonal antibodies.
    Tabrizi M; Funelas C; Suria H
    AAPS J; 2010 Dec; 12(4):592-601. PubMed ID: 20652780
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Translational strategies for development of monoclonal antibodies from discovery to the clinic.
    Tabrizi MA; Bornstein GG; Klakamp SL; Drake A; Knight R; Roskos L
    Drug Discov Today; 2009 Mar; 14(5-6):298-305. PubMed ID: 19152840
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Translational pharmacokinetics and pharmacodynamics of monoclonal antibodies.
    Kamath AV
    Drug Discov Today Technol; 2016; 21-22():75-83. PubMed ID: 27978991
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modeling, simulation, and translation framework for the preclinical development of monoclonal antibodies.
    Luu KT; Kraynov E; Kuang B; Vicini P; Zhong WZ
    AAPS J; 2013 Apr; 15(2):551-8. PubMed ID: 23408094
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and Clinical Pharmacology of Monoclonal Antibodies in Pediatric Patients.
    Temrikar ZH; Suryawanshi S; Meibohm B
    Paediatr Drugs; 2020 Apr; 22(2):199-216. PubMed ID: 32052309
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elimination mechanisms of therapeutic monoclonal antibodies.
    Tabrizi MA; Tseng CM; Roskos LK
    Drug Discov Today; 2006 Jan; 11(1-2):81-8. PubMed ID: 16478695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug Development of Therapeutic Monoclonal Antibodies.
    Mould DR; Meibohm B
    BioDrugs; 2016 Aug; 30(4):275-93. PubMed ID: 27342605
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical and clinical safety of monoclonal antibodies.
    Tabrizi MA; Roskos LK
    Drug Discov Today; 2007 Jul; 12(13-14):540-7. PubMed ID: 17631248
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fixed Dosing of Monoclonal Antibodies in Oncology.
    Hendrikx JJMA; Haanen JBAG; Voest EE; Schellens JHM; Huitema ADR; Beijnen JH
    Oncologist; 2017 Oct; 22(10):1212-1221. PubMed ID: 28754722
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monoclonal antibodies: what are the pharmacokinetic and pharmacodynamic considerations for drug development?
    Deng R; Jin F; Prabhu S; Iyer S
    Expert Opin Drug Metab Toxicol; 2012 Feb; 8(2):141-60. PubMed ID: 22248267
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of Shed/Soluble targets on the PK/PD of approved therapeutic monoclonal antibodies.
    Samineni D; Girish S; Li C
    Expert Rev Clin Pharmacol; 2016 Dec; 9(12):1557-1569. PubMed ID: 27766899
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Individualized Dosing of Therapeutic Monoclonal Antibodies-a Changing Treatment Paradigm?
    Strik AS; Wang YC; Ruff LE; Yashar W; Messmer BT; Mould DR
    AAPS J; 2018 Sep; 20(6):99. PubMed ID: 30187153
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dashboard systems: Pharmacokinetic/pharmacodynamic mediated dose optimization for monoclonal antibodies.
    Mould DR; Dubinsky MC
    J Clin Pharmacol; 2015 Mar; 55 Suppl 3():S51-9. PubMed ID: 25707964
    [TBL] [Abstract][Full Text] [Related]  

  • 14. "Fit-for-purpose" method validation and application of a biomarker (C-terminal telopeptides of type 1 collagen) in denosumab clinical studies.
    Wang J; Lee J; Burns D; Doherty D; Brunner L; Peterson M; DeSilva B
    AAPS J; 2009 Jun; 11(2):385-94. PubMed ID: 19462251
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and pharmacodynamics of monoclonal antibodies: concepts and lessons for drug development.
    Mould DR; Green B
    BioDrugs; 2010 Feb; 24(1):23-39. PubMed ID: 20055530
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Application and potential limitations of animal models utilized in the development of trastuzumab (Herceptin): a case study.
    Pegram M; Ngo D
    Adv Drug Deliv Rev; 2006 Aug; 58(5-6):723-34. PubMed ID: 16876287
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic drug-drug interaction potentials for therapeutic monoclonal antibodies: reality check.
    Seitz K; Zhou H
    J Clin Pharmacol; 2007 Sep; 47(9):1104-18. PubMed ID: 17766698
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The pharmacokinetics and pharmacodynamics of monoclonal antibodies--mechanistic modeling applied to drug development.
    Mould DR; Sweeney KR
    Curr Opin Drug Discov Devel; 2007 Jan; 10(1):84-96. PubMed ID: 17265746
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Surrogate approaches in development of monoclonal antibodies.
    Bornstein GG; Klakamp SL; Andrews L; Boyle WJ; Tabrizi M
    Drug Discov Today; 2009 Dec; 14(23-24):1159-65. PubMed ID: 19853060
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical pharmacology of trastuzumab.
    Levêque D; Gigou L; Bergerat JP
    Curr Clin Pharmacol; 2008 Jan; 3(1):51-5. PubMed ID: 18690878
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.